Baseline first positron emission tomography (PET)/computed tomography (CT) scan: positive 2-deoxy-2-(fluorine-18) fluoro-d-glucose (18F-FDG) PET/CT extrapulmonary disease sites in 358 patients
| PET/CT-positive patients n (%) | SUVmax | |||
| Range | Mean | Median | ||
| Brain | 34 (9.5) | 4.0–19.0 | 10.0 | 10.0 |
| Cardiac | 2 (0.6) | 3.2–13.8 | 8.5 | 8.5 |
| Pleura | 34 (9.5) | 2.6–17.7 | 7.1 | 6.7 |
| Muscles# | 10 (2.8) | 2.8–15.9 | 7.4 | 6.7 |
| Liver | 7 (2.0) | 3.8–23.3 | 12.4 | 13.1 |
| Spleen | 11 (3.1) | 2.7–20.1 | 5.2 | 3.5 |
| Gastrointestinal tract | 8 (2.2) | 3.4–17.4 | 4.8 | 9.3 |
| Urogenital tract | 7 (2.0) | 2.6–16.9 | 9.7 | 10.0 |
| Bone | 151 (42.2) | 2.5–32.8 | 9.5 | 8.1 |
| Lymph nodes | 225 (62.8) | 2.8–32.3 | 10.7 | 9.9 |
| Cervical | 108 (30.2) | 2.6–22.3 | 8.2 | 7.2 |
| Supraclavicular | 69 (19.3) | 3.1–24.4 | 8.4 | 6.9 |
| Axillary | 51 (14.2) | 2.5–20.0 | 7.1 | 5.8 |
| Mediastinal | 152 (42.4) | 2.5–21.2 | 6.9 | 5.9 |
| Hilar | 70 (19.6) | 2.7–23.0 | 6.3 | 5.3 |
| Retrocrural | 9 (2.5) | 2.7–15.7 | 6.4 | 5.3 |
| Retroperitoneal/mesenteric | 55 (15.4) | 3.0–16.1 | 7.0 | 6.4 |
| Pelvic | 28 (7.8) | 2.5–21.5 | 6.9 | 6.4 |
| Inguino-femoral | 18 (5.0) | 2.5–11.5 | 5.7 | 5.0 |
| Other sites¶ | 21 (5.9) | 2.5–32.0 | 7.5 | 5.7 |
Some patients had more than one organ involved. SUVmax: maximum standardised uptake value; SUVmax is a relative measure of FDG metabolism: 
; r: radioactivity concentration (kBq·mL−1); a′: decay-corrected amount of radiolabelled FDG (kBq); w: weight of patients (g). #: iliopsoas n=4, pectoral muscle n=1, posterior intercostal n=1, gluteal n=2, thigh n=1, obturator internus n=1; ¶: paravertebral mass/collection n=12 (SUVmax 2.5–9.8), adrenals n=3 (SUVmax 3.9–6.5), joint effusions n=3 (SUVmax 12.9–32), endometrium/ovary n=2 (SUVmax 4.1–7.1), focal bone marrow lesion n=1 (SUVmax 5.2).